Transgene SA (EPA:TNG)
France
· Delayed Price · Currency is EUR 0.6180
-0.0060 (-0.97%)
Apr 28, 2025, 11:07 AM CET
Transgene Revenue
In the year 2024, Transgene had annual revenue of 6.35M EUR, down -19.58%. Transgene had revenue of 3.00M in the half year ending December 31, 2024, a decrease of -29.62%.
Revenue
6.35M
Revenue Growth
-19.58%
P/S Ratio
12.83
Revenue / Employee
44.12K
Employees
144
Market Cap
81.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.35M | -1.55M | -19.58% |
| Dec 31, 2023 | 7.90M | -2.44M | -23.63% |
| Dec 31, 2022 | 10.34M | -6.90M | -40.00% |
| Dec 31, 2021 | 17.24M | 7.67M | 80.08% |
| Dec 31, 2020 | 9.57M | -3.72M | -28.00% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sanofi | 45.17B |
| Sartorius Stedim Biotech | 2.86B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| emeis Société anonyme | 5.64B |
Transgene News
- 7 months ago - Half Year 2024 Transgene SA Earnings Call Transcript - GuruFocus
- 1 year ago - Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript - Seeking Alpha
- 2 years ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 2 years ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire
- 2 years ago - Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 - Business Wire
- 2 years ago - BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 - Accesswire
- 2 years ago - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers - Business Wire
- 2 years ago - R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data - Business Wire